Introduction {#sec1}
============

Neuroblastoma, a common childhood extracranial tumor, originates from the developing sympathetic nervous system \[[@B1]\]. It mainly occurs in infancy, with the median age of 17 months at diagnosis \[[@B2]\]. In addition, neuroblastoma accounts for approximately 10% of all malignancies and 15% of malignancy deaths in children \[[@B3]\]. This type of childhood malignancy shows great heterogeneity in clinical presentation and prognosis. Neuroblastoma could be classified into low, intermediate, and high risk groups based on clinical and biological characteristics, including tumor stage, histopathology, age, DNA index, and MYCN amplification \[[@B4]\].

Moreover, several genome-wide association studies (GWASs) have identified extra neuroblastoma susceptibility genes, including *CASC15, BARD1, LMO1, DUSP12, HACE1, LIN28B, CPZ* and *RSRC1* \[[@B7]\]. Beside GWASs, candidate gene approaches also identified several candidate loci, such as, the *NEFL* rs1059111 polymorphism correlates with increased levels of *NEFL*, and confers protection against neuroblastoma development \[[@B13]\]. The *CDKN1B* rs34330 polymorphism acts as a genetic risk factor for neuroblastoma by affecting the transcription rate \[[@B14]\]. The *BARD1* rs17489363 and rs1048108 polymorphisms could influence neuroblastoma susceptibility \[[@B15]\].

MicroRNAs (miRNAs) are short non-coding RNAs (approximately 17--22 nucleotides in length. These small RNAs can bind to the 3′-untranslated region (3′-UTR) of gene transcripts to induce target mRNA degradation or inhibit translation \[[@B16]\]. miRNAs play important roles in carcinogenesis, including neuroblastoma \[[@B17]\]. DNA sequences encoding miRNAs include single miRNA gene loci, miRNA gene clusters, or fragments within introns of protein-coding genes. The primary miRNA (pri-miRNA) are processed to generate small mature miRNAs by the RNase III enzymes, Dicer and Drosha \[[@B21]\]. The single nucleotide polymorphisms (SNPs) in precursor miRNA (pre-miRNA) encoding sequences may influence miRNA expression and maturation, thereby modifying susceptibility to neuroblastoma and other cancers \[[@B22]\].

*Pre-miR-146a, pre-miR-149* and *pre-miR-196a2* have been reported as key factors for carcinogenesis due to their targeting on several vital genes \[[@B27],[@B28]\]. The *pre-miR-146a* rs2910164, *pre-miR-149* rs2292832 and *pre-miR-196a2* rs11614913 polymorphisms could influence their functions through altering miRNA maturation, expression, and/or efficiency of targeting \[[@B29]\]. Previous studies showed that *miR-146a* was related to regulation of TNF-α \[[@B30]\], *miR-149* could regulate the expression of MTHFR \[[@B31]\], and *miR-196a2* could target *ANXA1, DFFA* and *PDCD4* \[[@B32]\]. These three well-known pre-miRNAs polymorphisms have been reported to be associated with the pathogenesis of various diseases, such as breast cancer, colorectal cancer, hepatocellular carcinoma, and gastric cancer \[[@B33]\]. However, in our previous studies in Chinese children of Southern and North China, no significant association among these three pre-miRNAs' polymorphisms and neuroblastoma susceptibility was observed \[[@B25]\]. Herein, we performed a three-center hospital-based case--control study to test the association among these three pre-miRNAs' SNPs and neuroblastoma risk with 312 cases and 762 controls residing in East China.

Materials and methods {#sec2}
=====================

Study subjects {#sec2-1}
--------------

Participants were recruited from three hospitals: Children's Hospital of Nanjing Medical University (158 cases and 426 controls, Jiangsu province, China) \[[@B39]\], Anhui Provincial Children's Hospital (119 cases and 264 controls, Anhui province, China) \[[@B40]\], and The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University (36 cases and 72 controls, Wenzhou area) \[[@B41],[@B42]\]. A total of 313 cases and 762 controls were enrolled for the case--control study (Supplementary Table S1). The study was approved by the institutional review boards of Children's Hospital of Nanjing Medical University, Anhui Provincial Children's Hospital and The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University. The selection standard and details of the included participants are accessible in our previous studies \[[@B43]\]. All participants or their guardians provided written informed consent before the study.

SNPs selection and genotyping {#sec2-2}
-----------------------------

Three well-known polymorphisms (*miR-146a* rs2910164, *miR-149* rs2292832 and *miR-196a2* rs11614913) were selected. An online tool, SNPinfo (<http://snpinfo.niehs.nih.gov/>) was used to predict the functions of selected SNPs (Supplementary Table S2). DNA samples were extracted as previously described \[[@B45]\]. Briefly, DNA samples were diluted to a stock concentration of 10 ng/μl and added to 96-well plates. Genotyping for these three polymorphisms was carried out in a 384-well plate using TaqMan Real-Time PCR method \[[@B47],[@B48]\]. Moreover, 10% of the samples were randomly chosen for duplicate analyses and the results of quality control samples were 100% concordant.

Statistical analysis {#sec2-3}
--------------------

Deviation from Hardy--Weinberg equilibrium (HWE) in controls was calculated for the selected SNPs by goodness-of-ft χ^2^ test. Differences in the genotypes and demographics between cases and controls were assessed by χ^2^ test. To evaluate the association among the three selected SNPs and neuroblastoma susceptibility, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a multivariate logistic regression. Moreover, stratified analyses were evaluated by tumor sites, gender and age. A *P*\<0.05 was considered as statistically significant. All statistical tests were calculated using SAS software (v9.4; SAS Institute, Cary, NC, U.S.A.).

Results {#sec3}
=======

Participants' characteristics {#sec3-1}
-----------------------------

The clinical and demographic characteristics of 313 neuroblastoma cases and 762 controls are shown in Supplementary Table S1. There were no significant differences between neuroblastoma cases and controls in age (*P*=0.823) and gender (*P*=0.610).

Association between selected *miRNA* polymorphisms and neuroblastoma risk {#sec3-2}
-------------------------------------------------------------------------

As shown in [Table 1](#T1){ref-type="table"} and Supplementary Table S3, the genotype counts and association results of these three pre-miRNAs' polymorphisms (*pre*-*miR-146a* rs2910164, *pre*-*miR-149* rs2292832 and *pre*-*miR-196a2* rs11614913) were assessed. All of the three selected SNPs were in accordance with the HWE in controls. However, no significant association was observed among the three selected SNPs and neuroblastoma risk in the combined study population.

###### 

Association between selected miRNAs polymorphisms and neuroblastoma risk

  Genotype                      Cases (*n*=313)   Controls (*n*=762)   *P*[^1^](#T1TFN1){ref-type="table-fn"}   Crude OR (95% CI)   *P*     Adjusted OR (95% CI)[^2^](#T1TFN2){ref-type="table-fn"}   *P*[^2^](#T1TFN2){ref-type="table-fn"}
  ----------------------------- ----------------- -------------------- ---------------------------------------- ------------------- ------- --------------------------------------------------------- ----------------------------------------
  *miR146a* rs2910164 C\>G                                                                                                                                                                            
  CC                            114 (36.42)       272 (35.70)                                                   1.00                        1.00                                                      
  CG                            159 (50.80)       365 (47.90)                                                   1.04 (0.78--1.39)   0.792   1.05 (0.79--1.40)                                         0.758
  GG                            40 (12.78)        125 (16.40)                                                   0.76 (0.50--1.16)   0.206   0.76 (0.50--1.16)                                         0.199
  Additive                                                             0.314                                    0.91 (0.75--1.11)   0.345   0.91 (0.75--1.11)                                         0.345
  Dominant                      199 (63.58)       490 (64.30)          0.822                                    0.97 (0.74--1.27)   0.821   0.97 (0.74--1.28)                                         0.844
  Recessive                     270 (87.22)       637 (83.60)          0.134                                    0.75 (0.51--1.10)   0.135   0.74 (0.51--1.09)                                         0.125
  *miR-149* rs2292832 T\>C                                                                                                                                                                            
  TT                            226 (72.20)       542 (71.13)                                                   1.00                        1.00                                                      
  TC                            68 (21.73)        161 (21.13)                                                   1.01 (0.73--1.40)   0.938   1.01 (0.73--1.40)                                         0.944
  CC                            19 (6.07)         59 (7.74)                                                     0.77 (0.45--1.33)   0.348   0.78 (0.45--1.34)                                         0.362
  Additive                                                             0.629                                    0.93 (0.75--1.16)   0.504   0.93 (0.75--1.16)                                         0.515
  Dominant                      87 (27.80)        220 (28.87)          0.723                                    0.95 (0.71--1.27)   0.724   0.95 (0.71--1.27)                                         0.728
  Recessive                     294 (93.93)       703 (92.26)          0.337                                    0.77 (0.45--1.31)   0.338   0.78 (0.45--1.33)                                         0.353
  *miR-196a2* rs11614913 T\>C                                                                                                                                                                         
  TT                            89 (28.43)        230 (30.18)                                                   1.00                        1.00                                                      
  TC                            163 (52.08)       377 (49.48)                                                   1.12 (0.82--1.52)   0.477   1.12 (0.82--1.52)                                         0.478
  CC                            61 (19.49)        155 (20.34)                                                   1.02 (0.69--1.49)   0.931   1.02 (0.69--1.50)                                         0.922
  Additive                                                             0.738                                    1.02 (0.84--1.23)   0.848   1.02 (0.84--1.23)                                         0.840
  Dominant                      224 (71.57)       532 (69.82)          0.568                                    1.09 (0.81--1.46)   0.569   1.09 (0.81--1.46)                                         0.566
  Recessive                     252 (80.51)       607 (79.66)          0.751                                    0.95 (0.68--1.32)   0.751   0.95 (0.68--1.32)                                         0.762

χ^2^ test for genotype distributions between neuroblastoma cases and cancer-free controls.

Adjusted for age and gender.

Stratified analysis {#sec3-3}
-------------------

Next, participants were stratified in terms of tumor sites, gender, and age. Consistently, as shown in [Table 2](#T2){ref-type="table"}, there was no significant association for these three pre-miRNAs polymorphisms in subgroups (defined by tumor sites, gender, and age).

###### 

Stratification analysis for the association between selected polymorphism and neuroblastoma susceptibility

  Variables           rs2910164 (case/control)   AOR (95% CI)[^1^](#T2TFN1){ref-type="table-fn"}   *P*[^1^](#T2TFN1){ref-type="table-fn"}   rs2292832 (case/control)   AOR (95% CI)[^1^](#T2TFN1){ref-type="table-fn"}   *P*[^1^](#T2TFN1){ref-type="table-fn"}   rs11614913 (case/control)   AOR (95% CI)[^1^](#T2TFN1){ref-type="table-fn"}   *P*[^1^](#T2TFN1){ref-type="table-fn"}                                 
  ------------------- -------------------------- ------------------------------------------------- ---------------------------------------- -------------------------- ------------------------------------------------- ---------------------------------------- --------------------------- ------------------------------------------------- ---------------------------------------- --------- ------------------- -------
  Age, months                                                                                                                                                                                                                                                                                                                                                                                                          
    ≤18               124/283                    18/57                                             0.73 (0.41--1.29)                        0.271                      101/243                                           41/97                                    1.03 (0.67--1.59)           0.890                                             43/99                                    99/241    0.96 (0.62--1.47)   0.840
    \>18              149/354                    22/68                                             0.77 (0.46--1.29)                        0.318                      125/299                                           46/123                                   0.89 (0.60--1.33)           0.575                                             46/131                                   125/291   1.22 (0.82--1.82)   0.318
  Gender                                                                                                                                                                                                                                                                                                                                                                                                               
    Female            127/286                    18/54                                             0.75 (0.42--1.34)                        0.328                      108/247                                           37/93                                    0.93 (0.59--1.45)           0.731                                             47/101                                   98/239    0.90 (0.59--1.37)   0.610
    Male              146/351                    22/71                                             0.75 (0.45--1.25)                        0.271                      118/295                                           50/127                                   0.99 (0.67--1.46)           0.947                                             42/129                                   126/293   1.33 (0.88--1.99)   0.174
  Sites of origin                                                                                                                                                                                                                                                                                                                                                                                                      
    Adrenal gland     62/637                     6/125                                             0.49 (0.21--1.16)                        0.103                      50/542                                            18/220                                   0.88 (0.50--1.55)           0.668                                             18/230                                   50/532    1.19 (0.68--2.09)   0.538
    Retroperitoneal   107/637                    19/125                                            0.90 (0.53--1.52)                        0.691                      91/542                                            35/220                                   0.96 (0.63--1.46)           0.833                                             37/230                                   89/532    1.04 (0.69--1.57)   0.855
    Mediastinum       87/637                     12/125                                            0.70 (0.37--1.32)                        0.271                      71/542                                            28/220                                   0.98 (0.61--1.55)           0.920                                             28/230                                   71/532    1.09 (0.69--1.74)   0.706
    Others            17/637                     3/125                                             0.88 (0.25--3.05)                        0.836                      14/542                                            6/220                                    1.07 (0.41--2.83)           0.893                                             6/230                                    14/532    0.98 (0.37--2.59)   0.966

Abbreviation: AOR, adjusted OR; CI, confidence interval.

Adjusted for age and gender, omitting the corresponding stratification factor.

Discussion {#sec4}
==========

In this three-center case--control study of neuroblastoma, we investigated the association of three well-known pre-miRNAs' polymorphisms with neuroblastoma risk in Eastern Chinese children. To our knowledge, this is the first replication study for the first time in Eastern Chinese children, regarding such association.

miRNAs could negatively regulate gene expression by binding 3′-UTR of target mRNAs and subsequently affect cell differentiation, proliferation \[[@B49]\]. *miR-146a* rs2910164 G\>C, *miR-149* rs2292832 C\>T and *miR-196a2* rs11614913 T\>C polymorphisms have been reported to be associated with the risk of breast, lung, thyroid, and gastric cancer \[[@B50],[@B51]\]. Further studies found that the *miR-196a2* rs11614913 polymorphism was significantly associated with the developing cancer risk \[[@B52],[@B53]\]. According to recent reports, the *miR-146a, miR-149, miR-196a2* polymorphisms may be genetic predisposing factors in different diseases \[[@B33],[@B34],[@B54]\]. The *miR-146a, miR-149* and *miR-196a2* polymorphisms were significantly associated with the expression of TNF-α, Annexin A1, C-reactive protein, and MTHFR \[[@B50]\]. However, in our previous study in South and North China, no significant association among these three pre-miRNAs polymorphisms (*miR146a* rs2910164, *miR-149* rs2292832, and *miR-196a2* rs11614913) and neuroblastoma susceptibility was observed \[[@B25]\].

Herein, we also observed no significant association of these three pre-miRNAs SNPs with neuroblastoma risk in the Eastern Chinese populations. Several limitations existed in the present study. First, the present study population only included Eastern Chinese individuals, and the results need to be validated in other ethnic groups. Second, the statistical power may be limited due to small sample size. Third, because of the retrospective study, selection and information bias might be unavoidable. Finally, most SNPs only have weak effects on tumor risk \[[@B55],[@B56]\]. Only three polymorphisms were investigated in the present study. Some potentially functional SNPs remain to be assessed in the future.

In conclusion, our study showed that three pre-miRNAs polymorphisms (*pre-miR-146a* rs2910164, *pre-miR-149* rs2292832 and *pre-miR-196a2* rs11614913) are not associated with neuroblastoma risk in Eastern Chinese children. Therefore, additional studies with larger sample size are required to fully understand the role of the three pre-miRNAs' polymorphisms in neuroblastoma susceptibility.
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